BioSpace News Archive

The global surgical cutting devices market is expected to post a CAGR of close to 5% during the period 2019-2023, according to the latest market research report by Technavio.

Innovative application provides actionable patient information for healthcare providers, networks

Achieve Life Sciences, Inc. announced it has extended its strategic collaboration with the National Center for Complementary and Integrative Health at the National Institutes of Health.

Stero Biotechs, an Israel-based, clinical-stage company focused on Cannabidiol formulation research and development, received its second Helsinki approval to move forward with a second Phase 2a clinical trial.

TARGET BP Clinical Program studies renal denervation using the investigational Peregrine System Kit

Arkivum, announced it has achieved pharma-level compliance with the award of ISO 9001:2015 certification, demonstrated alignment with data-related GxP regulations, re-certification of ISO 27001:2017 and successfully completing pharma audits initiated by pharma companies.

New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia or atherosclerotic cardiovascular disease, experienced more heart attacks, strokes and other cardiovascular events when they were unable to obtain their prescribed PCSK9 inhibitor, a cholesterol-lowering treatment.

The need for quality patient care has increased owing to the growing aging population and the consequent rise in chronic diseases.

Dr. Reddy’s Laboratories Ltd. announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem® (ramelteon, 8 mg) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

ONPATTRO® is the Only Treatment that Demonstrated Improvement, Relative to Baseline, in both Polyneuropathy and Quality of Life Measures in Patients1, 2 with hATTR Amyloidosis